Kidney Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are 18 years old or older and have been diagnosed with kidney cancer that has spread to other parts of the body (metastatic renal cell carcinoma)
- You are currently receiving a type of cancer treatment called immunotherapy (immune checkpoint inhibitor therapy), and your scans suggest the cancer may be progressing or staying stable in a specific way under immunotherapy guidelines (confirm with trial site)
- You have two or more tumors or affected areas that doctors can measure using scans (CT or MRI), physical examination, or visual inspection — note that certain bone-only lesions without a measurable soft-tissue part do not count
- You are planned to have a specific targeted treatment called IGU delivered to one of your tumor sites (confirm with trial site)
- You are willing and able to sign a consent form after being fully informed about the study — someone else may sign on your behalf if you are physically unable to do so
Who may not be able to join:
- You currently have, or have recently had within the last 2 years, a second separate cancer — though there are several exceptions for early-stage cancers or cancers considered fully cured, so please confirm your specific situation with the trial site
- You have serious other health conditions, such as severe heart disease, a heart attack within the last 6 months, diabetes that cannot be controlled even with insulin, uncontrolled high blood pressure, an active infection, severe bowel problems, an autoimmune disease, or any other major serious health condition
- Your chest X-ray or CT scan shows clear signs of a specific type of long-term lung scarring condition (idiopathic interstitial pneumonia) (confirm with trial site)
- You currently have an active (acute) lung infection or pneumonia
- You have a mental health condition or symptoms that doctors feel would make it too difficult for you to take part in the study safely
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Hiroshi Onishi, MD, PhD, University of Yamanashi
Phone: +81-55-273-1111
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Abscopal Response Rate (ARR) at 1 Year After IGU
Can't join this trial?
Data last synced from ClinicalTrials.gov: 9 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.